Avicanna Inc. Stock OTC Markets

AVCNF

CA05368K1003

Biotechnology & Medical Research

Market Closed - OTC Markets 00:13:59 21/08/2026 HKT			5-day change	1st Jan Change
0.0941 ^USD	-1.90%		+1.73%	-41.95%

08-20	Avicanna Inc. announced that it has received CAD 0.5 million in funding	CI
08-19	Avicanna Closes C$500,000 Private Placement to Pharmaceutical Investor Michael Porter	MT

Last Transcript: Avicanna Inc.

Avicanna Inc. - Shareholder/Analyst Call

05-10

More transcripts

Managers and Directors: Avicanna Inc.

Manager	Title	Age	Since
Ivana Maric SAM	Sales & Marketing	-	01/05/2015
Aras Azadian CEO	Chief Executive Officer	39	26/11/2016
Nick Hilborn DFI	Director of Finance/CFO	-	15/09/2025

Director	Title	Age	Since
Aras Azadian CHM	Chairman	39	26/11/2016
Giancarlo Davila Char BRD	Director/Board Member	-	22/10/2018
Michael Kott BRD	Director/Board Member	-	01/01/2026

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AVICANNA INC.	-1.90%	+1.73%	-	-	12.64M
LONZA GROUP AG	+1.14%	+2.27%	+2.38%	+24.14%	50.5B
REVOLUTION MEDICINES, INC.	-1.36%	+4.82%	+485.55%	+614.84%	46.01B
BEONE MEDICINES AG	-2.04%	+3.69%	+19.34%	+91.23%	42.85B
IQVIA HOLDINGS INC.	+2.72%	+6.02%	+33.33%	+19.66%	41.03B
CELLTRION, INC.	0.00%	-3.91%	+18.49%	+47.98%	32.02B
ASCENDIS PHARMA A/S	-1.85%	+3.48%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+0.72%	+5.27%	+31.55%	+145.37%	16.98B
EUROFINS SCIENTIFIC SE	+3.06%	+3.88%	+5.81%	+35.00%	14.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.50%	+3.62%	+82.64%	+46.53%	13.84B
Average	+0.10%	+2.92%	+84.89%	+128.09%	30.51B
Weighted average by Cap.	+0.18%	+2.74%	+104.88%	+152.88%

See all sector performances

Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.

Employees

112

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
20/08/26	US$0.0941	-1.90%	1,900
19/08/26	US$0.0959	+2.67%	100,400
18/08/26	US$0.0934	-2.24%	200
17/08/26	US$0.0955	-0.38%	14,600
14/08/26	US$0.0959	+3.68%	100

Delayed Quote OTC Markets

More quotes

As early as today, start finding the best investment opportunities!

Market Cap	18.59M 13.5M 11.56M 10.78M 9.89M 1.29B 18.96M 128M 49.87M 647M 50.68M 49.58M 2.14B	P/E 2024	-8.43x	P/E 2025	-9.36x
Enterprise Value	18.31M 13.29M 11.38M 10.62M 9.74M 1.27B 18.67M 126M 49.11M 637M 49.92M 48.83M 2.11B	EV / Sales 2024	1.31x	EV / Sales 2025	1.03x
Free-Float	78.18%	Yield 2024 *	-	Yield 2025	-

08-20	Avicanna Inc. announced that it has received CAD 0.5 million in funding	CI
08-19	Avicanna Closes C$500,000 Private Placement to Pharmaceutical Investor Michael Porter	MT
08-15	Avicanna Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-15	Avicanna Inc Announces Board Changes	CI
07-17	Avicanna Launching Rapid Onset Medical Cannabis Portfolio in Canada	MT
07-16	Avicanna Introduces Quix Rapid-Onset Medical Cannabis Portfolio	CI
07-01	Avicanna Inc. Promotes Nick Hilborn to Chief Financial Officer, Effective June 30, 2026	CI
05-14	Avicanna Swings to Net Comprehensive Loss in Q1	MT
05-14	Earnings Flash (AVCN.TO) Avicanna Reports Q1 Revenue $6.7M, Up 6% YoY and Highest Ever	MT
05-14	Avicanna Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-10	Avicanna Inc. - Shareholder/Analyst Call
05-02	Avicanna Inc. Announces Resignation of Eileen McCormack as A Member of the Board of Directors , Effective May 1, 2026	CI
04-30	Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification	RE

08-19	Avicanna Announces Closing of Strategic Non-Brokered Private Placement	AQ
08-17	Avicanna Reports Q2 2026 Financial Results	AQ
08-15	Avicanna Reports Q2 2026 Financial Results	AQ
07-16	Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio	AQ
07-01	Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer	AQ

1 day	-1.90%
1 week	+1.73%
Current month	+1.51%
1 month	-1.77%
3 months	-5.90%
6 months	-24.11%
Current year	-41.95%

1 week	0.09	0.1
1 month	0.09	0.1
Current year	0.07	0.18
1 year	0.07	0.24
3 years	0.07	0.53
5 years	0.07	1.08
10 years	0	3.53

Avicanna Inc. Stock OTC Markets

Stocks

AVCNF

CA05368K1003

Biotechnology & Medical Research

Valuation: Avicanna Inc.

Chart: Avicanna Inc.

Latest news : Avicanna Inc.

Last Transcript: Avicanna Inc.

Press Releases: Avicanna Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Avicanna Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

	2024	2025
Net sales	25.46M 18.48M 15.83M 14.77M 13.55M 1.77B 25.96M 175M 68.28M 886M 69.4M 67.89M 2.93B	25.48M 18.5M 15.84M 14.78M 13.56M 1.77B 25.98M 175M 68.34M 887M 69.46M 67.94M 2.94B
Net income	-3.62M -2.63M -2.25M -2.1M -1.93M -251M -3.69M -24.89M -9.7M -126M -9.86M -9.65M -417M	-2.76M -2M -1.72M -1.6M -1.47M -192M -2.81M -18.98M -7.4M -96.06M -7.52M -7.36M -318M
Net Debt	-339K -246K -211K -196K -180K -23.54M -345K -2.33M -909K -11.8M -924K -903K -39.05M	-281K -204K -174K -163K -149K -19.49M -286K -1.93M -753K -9.77M -765K -748K -32.35M